Patent intelligence · US
US 9833508
Cancer therapeutics
Cancer therapeutics
Patent details — US 9833508
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 5, 2017
- Expiration
- Nov 30, 2037
- Applicant
- IMMIX BIOPHARMA, INC.
- Claims
- 6
- CPC classes
- A61K, A61K31/12, A61K31/713, A61K39/3955
Quick answer
US 9833508 (Cancer therapeutics) is held by IMMIX BIOPHARMA, INC.. Status: granted. Granted Dec 5, 2017. Expires Nov 30, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- IMMIX BIOPHARMA, INC.
- Grant date
- Expiration
- Claims
- 6
- CPC classes
- A61K, A61K31/12, A61K31/713, A61K39/3955, A61K47/6849, A61K47/6851
More from IMMIX BIOPHARMA, INC.
Related pharmaceutical patents in our USPTO index.
Related coverage
Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?
While many drugmakers are focused on lung cancer for PD-1/VEGF bispecifics, emerging evidence shows the liver may offer higher value. This analysis covers the mechanism, key players, and strategic implications for pharma teams.
FDA Approves Tislelizumab (Tevimbra) for First-Line Advanced Esophageal Cancer
FDA approves Tislelizumab with chemotherapy for first-line advanced esophageal squamous cell carcinoma (ESCC), targeting PD-L1 positive tumors.
Frequently asked questions
What is US patent 9833508?
US 9833508 (Cancer therapeutics) is held by IMMIX BIOPHARMA, INC.. Status: granted. Granted Dec 5, 2017. Expires Nov 30, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9833508?
IMMIX BIOPHARMA, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 2 pharmaceutical patents for this assignee.
When does US 9833508 expire?
Our index shows an expiration date of Nov 30, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.